145 related articles for article (PubMed ID: 14663359)
1. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas.
Ghorab Z; Jorda M; Ganjei P; Nadji M
Appl Immunohistochem Mol Morphol; 2003 Dec; 11(4):330-3. PubMed ID: 14663359
[TBL] [Abstract][Full Text] [Related]
2. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors.
Renshaw AA; Granter SR
Mod Pathol; 1998 Dec; 11(12):1160-4. PubMed ID: 9872645
[TBL] [Abstract][Full Text] [Related]
3. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases.
Loy TS; Phillips RW; Linder CL
Arch Pathol Lab Med; 2002 Feb; 126(2):170-2. PubMed ID: 11825112
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.
Busam KJ; Iversen K; Coplan KA; Old LJ; Stockert E; Chen YT; McGregor D; Jungbluth A
Am J Surg Pathol; 1998 Jan; 22(1):57-63. PubMed ID: 9422316
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of A103 and inhibin-alpha in adrenocortical tumors: an immunohistochemical study using tissue microarray techniques].
Zhang HY; Wang XJ; Liu WP; Jiang LL; Li GD; Guo J; Zhang YH
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):203-7. PubMed ID: 15256108
[TBL] [Abstract][Full Text] [Related]
6. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique.
Pan CC; Chen PC; Tsay SH; Ho DM
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):347-52. PubMed ID: 16280664
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors.
Zhang H; Bu H; Chen H; Wei B; Liu W; Guo J; Li F; Liao D; Tang Y; Zhang Z
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):32-9. PubMed ID: 18091323
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.
Mete O; Kapran Y; Güllüoğlu MG; Kiliçaslan I; Erbil Y; Senyürek YG; Dizdaroğlu F
Virchows Arch; 2010 May; 456(5):515-21. PubMed ID: 20390424
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody.
Tartour E; Caillou B; Tenenbaum F; Schröder S; Luciani S; Talbot M; Schlumberger M
Cancer; 1993 Dec; 72(11):3296-303. PubMed ID: 8242556
[TBL] [Abstract][Full Text] [Related]
10. Immunoreactivity of A103, an antibody to Melan A, in canine steroid-producing tissues and their tumors.
Ramos-Vara JA; Beissenherz ME; Miller MA; Johnson GC; Kreeger JM; Pace LW; Turk JR; Turnquist SE; Watson GL; Yamini B
J Vet Diagn Invest; 2001 Jul; 13(4):328-32. PubMed ID: 11478605
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
12. Melan-A (A103) and inhibin expression in ovarian neoplasms.
Yao DX; Soslow RA; Hedvat CV; Leitao M; Baergen RN
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):244-9. PubMed ID: 12966351
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical differential diagnosis of adrenocortical neoplasms using the monoclonal antibody D11.
Schröder S; Niendorf A; Achilles E; Dietel M; Padberg BC; Beisiegel U; Dralle H; Bressel M; Klöppel G
Virchows Arch A Pathol Anat Histopathol; 1990; 417(2):89-96. PubMed ID: 2114700
[TBL] [Abstract][Full Text] [Related]
14. Melan-A, a new melanocytic differentiation marker.
Busam KJ; Jungbluth AA
Adv Anat Pathol; 1999 Jan; 6(1):12-8. PubMed ID: 10197235
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin expression in adrenocortical neoplasia: an immunohistochemical and biochemical study with implications for the differential diagnosis of adrenocortical, hepatocellular, and renal cell carcinoma.
Gaffey MJ; Traweek ST; Mills SE; Travis WD; Lack EE; Medeiros LJ; Weiss LM
Hum Pathol; 1992 Feb; 23(2):144-53. PubMed ID: 1371262
[TBL] [Abstract][Full Text] [Related]
16. Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas.
Jorda M; De MB; Nadji M
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):67-70. PubMed ID: 11893039
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of the monoclonal antibody A103 in fine-needle aspiration biopsies of the adrenal.
Shin SJ; Hoda RS; Ying L; DeLellis RA
Am J Clin Pathol; 2000 Feb; 113(2):295-302. PubMed ID: 10664633
[TBL] [Abstract][Full Text] [Related]
18. Histologic and immunohistochemical classification of 41 bovine adrenal gland neoplasms.
Grossi AB; Leifsson PS; Jensen HE; Vainer B; Iburg T
Vet Pathol; 2013 May; 50(3):534-42. PubMed ID: 23242804
[TBL] [Abstract][Full Text] [Related]
19. Anti-alpha-inhibin: marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration.
Fetsch PA; Powers CN; Zakowski MF; Abati A
Cancer; 1999 Jun; 87(3):168-72. PubMed ID: 10385449
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms.
Goldblum JR; Shannon R; Kaldjian EP; Thiny M; Davenport R; Thompson N; Lloyd RV
Mod Pathol; 1993 Nov; 6(6):663-8. PubMed ID: 7508113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
